Published on
May 9, 2024
- 19:23 GMT
Mabylon AG Announces Development Candidate Nomination of an Anti-Allergen Multispecific Antibody for Peanut Allergy
SCHLIEREN, ZURICH, SWITZERLAND, May 9, 2024 /EINPresswire.com/ -- Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced the nomination of an anti-allergen multispecific …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
